文献速递浆细胞疾病造血干细胞移植与细胞治疗

新诊断多发性骨髓瘤患者自体干细胞移植后维持治疗对Connect MM研究结局的影响

Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
PubMed 文献 · Blood Adv · 2018-01-01

基于美国Connect MM观察性注册研究2009至2011年入组的1450例新诊断多发性骨髓瘤患者,分析接受诱导治疗及自体干细胞移植的432例患者(自移植后100天起分析),其中267例接受维持治疗(80%以来那度胺为基础,其中88%为来那度胺单药),165例未接受维持治疗。来那度胺维持治疗较无维持治疗改善中位无进展生存期(50.3 vs 30.8个月)和3年无进展生存率(56% vs 42%),并改善中位总生存期(两组均未达到)和3年总生存率(85% vs 70%)。

要点

  • 来那度胺维持治疗较无维持治疗改善中位无进展生存期(50.3 vs 30.8个月,HR 0.62)。
  • 来那度胺维持治疗较无维持治疗改善3年无进展生存率(56% vs 42%)和3年总生存率(85% vs 70%)。
  • 来那度胺维持治疗组报告5例血液学严重不良事件,无维持治疗组报告1例。

核心结论

  • 在基于社区的Connect MM注册研究中,观察到临床试验中已证实的来那度胺维持治疗生存获益。

研究设计与样本

  • 利用美国最大的新诊断多发性骨髓瘤观察性注册研究Connect MM的数据,分析2009至2011年入组的1450例接受治疗患者。
  • 接受诱导治疗及自体干细胞移植的患者(n=432)自移植后100天起进行分析(数据截止2016年1月7日):267例接受维持治疗(80%以来那度胺为基础,其中88%接受来那度胺单药),165例未接受维持治疗。

主要发现

  • 来那度胺维持治疗组较无维持治疗组改善中位无进展生存期(50.3 vs 30.8个月;HR 0.62;95%CI 0.46-0.82;P<.001)和3年无进展生存率(56% vs 42%)。
  • 来那度胺维持治疗组较无维持治疗组改善中位总生存期(两组均未达到;HR 0.54;95%CI 0.36-0.83;P=.005)和3年总生存率(85% vs 70%)。
  • 来那度胺维持治疗组报告5例血液学严重不良事件(全血细胞减少2例,发热性中性粒细胞减少、贫血和血小板减少各1例),无维持治疗组报告1例血小板减少。
  • 来那度胺维持治疗组和无维持治疗组的第二原发恶性肿瘤发生率分别为每患者年1.38和2.19起事件。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011. Patients who received induction therapy and ASCT (n = 432) were analyzed from 100 days post-ASCT (data cut 7 January 2016): 267 received maintenance (80% lenalidomide-based [of whom 88% received lenalidomide monotherapy]); 165 did not. Lenalidomide maintenance improved median PFS and 3-year PFS rate vs no maintenance (50.3 vs 30.8 months [hazard ratio (HR), 0.62; 95% confidence interval (CI), 0.46-0.82; P < .001] and 56% vs 42%, respectively). Improvements in median OS and 3-year OS rate were associated with lenalidomide maintenance vs no maintenance (not reached in either group [HR, 0.54; 95% CI, 0.36-0.83; P = .005] and 85% vs 70%, respectively). Five hematologic serious adverse events were reported with lenalidomide maintenance (pancytopenia [n = 2], febrile neutropenia, anemia, and thrombocytopenia [n = 1 each]) and 1 with no maintenance (thrombocytopenia). Second primary malignancies occurred at rates of 1.38 and 2.19 events per patient-year in lenalidomide maintenance and no maintenance groups, respectively. Survival benefits associated with lenalidomide maintenance previously demonstrated in clinical trials were observed in this community-based Connect MM Registry.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jagannath S, Abonour R, Durie BGM, et al. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM. Blood Adv. 2018. PMID: 29986853. doi:10.1182/bloodadvances.2018017186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。